UHN Commercialization is committed to converting our top-tier science into products and treatments with the potential to impact patients worldwide. To this end, UHN’s technology incubation model includes in-house gap funding programs offering significant capital to help early-stage technologies advance to the point of commercialization readiness.
Programs such as the Innovation Acceleration Fund, in partnership with the Princess Margaret Cancer Foundation, help researchers close funding gaps between research funding received from grant and government sources, and the significant private-sector investments needed to de-risk discoveries in order to bring new therapies and technologies to the people who need them.
The Princess Margaret Cancer Centre’s Innovation Acceleration Fund (IAF) has been established to overcome barriers to research translation. Its objective is to accelerate research discoveries made by Princess Margaret Cancer Centre researchers to demonstrate commercial applicability to potential industry partners.
A maximum of $250,000 is available per proposal. Eligible researchers affiliated with the Princess Margaret Cancer Center can learn more here or by contacting Brian Bobechko, Business Development and Commercialization Principal at IAFinfo@tdc.uhnresearch.ca
Are you a researcher at the Princess Margaret Cancer Centre? Think your project can accelerate cutting edge cancer research from bench to bedside? With the IAF, early stage research with high commercialization potential receives critical funds to advance and help patients worldwide.
Questions? Contact us at : IAFinfo@tdc.uhnresearch.ca